XL092 (Not yet branded)
Other Medications
Description
XL092 is a multi-kinase inhibitor being developed for the treatment of metastatic colorectal cancer, particularly in patients with microsatellite stable (MSS) tumors. This oral targeted therapy is designed to block multiple signaling pathways involved in tumor growth and angiogenesis. In colorectal cancer, XL092 has been evaluated as both monotherapy and in combination with the immunotherapy agent atezolizumab, positioning it as a potential alternative to regorafenib for advanced disease.
Mechanism of Action
XL092 functions as a multi-targeted tyrosine kinase inhibitor that blocks several key pathways involved in tumor progression and blood vessel formation. The drug targets multiple kinases including VEGFR, PDGFR, and other growth factor receptors that promote cancer cell proliferation and angiogenesis. By simultaneously inhibiting these pathways, XL092 aims to reduce tumor growth while cutting off the blood supply that feeds cancer cells.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Not yet branded |
| Category | Other Medications |
 Status | Experimental |
 EMA Status | Experimental |
 Spain Access | Not available |
| Administration | Oral |
| Clinical Trials | 2 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.